Double-Dose eye injections tested for two leading causes of blindness
NCT ID NCT06591598
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 4 study tested how much of the drug aflibercept gets into the bloodstream when a high dose (8 mg) is injected into both eyes of adults with diabetic macular edema or wet age-related macular degeneration. Fifty-one participants received the injections and had blood samples taken to measure drug levels. The goal was to gather more safety and exposure data, not to directly measure vision improvement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aflibercept (Eylea HD)
What this could lead to
If successful, this study could confirm that high-dose aflibercept is safe and effective when given to both eyes at once, potentially simplifying treatment for people with DME or wet AMD.
What could go wrong
This is a small, completed pharmacokinetic study (51 people) focused on drug levels, not on long-term safety or vision outcomes. Results may not apply to all patients or guarantee better vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Axon Clinical, s.r.o.
Prague, 150 00, Czechia
-
Budapest Retina Associates
Budapest, 1133, Hungary
-
Debreceni Egyetem Klinikai Kozpont
Debrecen, 4032, Hungary
-
Fakultna nemocnica s poliklinikou Zilina
Žilina, 012 07, Slovakia
-
Fakultní nemocnice Královské Vinohrady - Urologická klinikay
Prague, 10034, Czechia
-
Univerzitna nemocnica Bratislava, Nem. Sv. Cyrila a Metoda
Bratislava, 851 07, Slovakia